COMMUNIQUÉS West-GlobeNewswire

Avricore Appoints Rodger Seccombe as CEO
05/06/2025
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the " Company " or “ Avricore ”) is pleased to report the appointment of Rodger Seccombe as CEO of the Company. Mr. [...]
Attention Craft Beer Fans! Tilray Beverages Highlights Boldest Brews For Summer
05/06/2025
Explore Craft Beers from Atwater Brewery, Blue Point Brewing, Breckenridge Brewery, Montauk Brewing, Shock Top, SweetWater Brewing Co., Terrapin Beer Co., and Widmer Brother’s Brewing—Perfectly Crafted for the Sunny [...]
Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
05/06/2025
WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today [...]
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
05/06/2025
– KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 – – KPL-387 Phase 1 single ascending dose data support profile for monthly dosing – – Presentation and webcast at Jefferies [...]
MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
05/06/2025
TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm"), a pharmaceutical company specialized in precision-based cannabinoids, announced the closing of the [...]
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
05/06/2025
Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- [...]
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
05/06/2025
Upfront fees and near-term development milestone payments totaling up to $11 million Sales milestones of $150 million or more in first 10 years of commercialization Royalties equaling 25% of net sales Ocugen to [...]
The Joint Corp. Announces $5 Million Stock Repurchase Program
05/06/2025
SCOTTSDALE, Ariz., June 05, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic ® network, announced that its board of directors has [...]
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
05/06/2025
Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated [...]
Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
05/06/2025
- DYNE-302 Demonstrated Functional Improvement in an FSHD Preclinical Model - WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life- [...]
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
05/06/2025
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZ TM has been granted [...]
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association®
05/06/2025
Four presentations on MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, including two clinical data presentations Additional preclinical presentations on other differentiated portfolio assets [...]
Kailera Therapeutics Appoints Adam Koppel and Christopher Hite to Board of Directors
05/06/2025
BOSTON and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of [...]
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
05/06/2025
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE [...]
L’administration d’une seule perfusion de CARVYKTI®▼ (ciltacabtagène autoleucel ; cilta-cel) a permis d’obtenir des rémissions durables sans traitement pendant au moins cinq ans chez des patients atteints d’un myélome multiple récidivant ou réfractaire
05/06/2025
De nouvelles données à long terme issues de l’étude CARTITUDE-1 montrent qu’un tiers des patients traités par cilta-cel restent sans progression de la maladie à cinq ans 1 L’analyse CARTITUDE-4 montre des bénéfices en [...]
Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty
05/06/2025
As a member of Medicines for Europe, Polpharma Group joins industry leaders in calling on EU Prime Ministers to adopt a 5-Point Pharmaceutical Action Plan to protect patients, boost manufacturing, and ensure fair [...]
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
05/06/2025
NAARDEN, The Netherlands and MIAMI, June 05, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Cocrystal Pharma’s Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference
05/06/2025
BOTHELL, Wash., June 05, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc . (Nasdaq: COCP) announces that its broad-spectrum protease inhibitor CDI-988 will be featured in an oral presentation at the 2025 Military Health [...]
ViGeneron Rebrands as VeonGen Therapeutics and Announces FDA Rare Pediatric Disease Designation and Clinical Progress for Lead Gene Therapy VG801 in Stargardt Disease
05/06/2025
VeonGen advances two proprietary, first-in-class gene therapies in the clinic, enabled by its novel vgRNA REVeRT and vgAAV technology platforms Lead program VG801 receives FDA Rare Pediatric Disease Designation and is [...]

Pages